Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections

PLoS One. 2015 Apr 24;10(4):e0119956. doi: 10.1371/journal.pone.0119956. eCollection 2015.

Abstract

Objectives: Complicated intra-abdominal infection (cIAI) is infection that extends beyond the hollow viscus of origin into the peritoneal space, and is associated with either abscess formation or peritonitis. There are few studies that have assessed the actual costs and outcomes associated with failure of initial antibiotic therapy for cIAI. The aims of this study were to evaluate risk factors and impact on costs and outcomes of failure of initial antibiotic therapy for community-onset cIAI.

Methods: A retrospective study was performed at eleven tertiary-care hospitals. Hospitalized adults with community-onset cIAI who underwent an appropriate source control procedure between August 2008 and September 2011 were included. Failure of initial antibiotic therapy was defined as a change of antibiotics due to a lack of improvement of the clinical symptoms and signs associated with cIAI in the first week.

Results: A total of 514 patients hospitalized for community-onset cIAI were included in the analysis. The mean age of the patients was 53.3 ± 17.6 years, 72 patients (14%) had health care-associated infection, and 48 (9%) experienced failure of initial antibiotic therapy. Failure of initial antibiotic therapy was associated with increased costs and morbidity. After adjustment for covariates, patients with unsuccessful initial therapy received an additional 2.9 days of parenteral antibiotic therapy, were hospitalized for an additional 5.3 days, and incurred $3,287 in additional inpatient charges. Independent risk factors for failure of initial antibiotic therapy were health care-associated infection, solid cancer, and APACHE II ≥13.

Conclusions: To improve outcomes and costs in patients with community-onset cIAI, rapid assessment of health care-associated risk factors and severity of disease, selection of an appropriate antibiotic regimen accordingly, and early infection source control should be performed.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / epidemiology*
  • Community-Acquired Infections / etiology
  • Female
  • Health Care Costs
  • Hospitalization
  • Humans
  • Intraabdominal Infections / drug therapy*
  • Intraabdominal Infections / epidemiology*
  • Intraabdominal Infections / etiology
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Tertiary Care Centers
  • Treatment Failure
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents

Grants and funding

This study was sponsored by Pfizer Pharmaceuticals Korea Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.